Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Investigational New Drugs

Volumn 23, Issue 6, 2005, Pages 563-567

  Dowlati, Afshin ^a   Chapman, Robert ^b   Subbiah, Shanmuga ^a   Fu, Pingfu ^a   Ness, Anne ^a   Cortas, Tania ^a   Patrick, Lauren ^a   Reynolds, Sherrie ^a   Xu, Natalie ^a   Levitan, Nathan ^a   Ivy, Percy ^c   Remick, Scot C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Ford Hospital   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Non small cell lung cancer; Phase II clinical trial; Rebeccamycin

Indexed keywords

REBECCAMYCIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 31544457090     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-0754-6     Document Type: Article

References (22)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics 2002. CA Cancer J Clin 52: 23-47, 2002
2. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R, Doll R: Tobacco and cancer: Recent epidemiological evidence. J Natl Cancer Inst 96: 99-106, 2004
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics 2004. CA Cancer J Clin 84-8-29, 2004
4. Idhe DC, Minna JD: Non-small cell lung cancer, part I: Biology, diagnosis, and staging. Curr Probl Cancer 15: 61-104, 1991
5. Juretic A, Sobat H, Samija M: Combined modality therapy of non-small lung cancers. Ann Oncol 10: 93-98. 1999
6. Boring C, Squires T, Tong T, Montgomery S: Cancer statistics 1994. CA Cancer J Clin 44: 7-26, 1994
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000
8. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000
9. Kaneko T, Wong H, Okamoto KT, Clardy J: Two synthetic approaches to rebeccamycin. Tetrahedron Lett 26: 4015-4018, 1985
10. Nettledone DE, Doyle W, Krishnan B, Matsumoto K, Clardy J: Isolation and structure of rebeccamycin - a new antitumor antibiotic from Nocardia aerocolonigenes. Tetrahedron Lett 26: 4011-1014, 1985
11. Kaneko T, Wong H, Utzig J, Schurig J, Doyle T: Water-soluble derivatives of rebeccamycin. J Antibiot 40: 668-678, 1987
12. Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G: Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res 8: 2193-2201, 2002
13. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK: Phase I and pharmcokinetic study of NSC 655649, a rebeccamycin analogue with topoisomerase inhibitory properties. J Clin Oncol 19: 2937-2947, 2001
14. Dowlati A, Hoppel CL, Ingalls ST, Majka S, Li X, Sedransk N, Spiro T, Gerson SL, Ivy P, Remick SC: Phase I clinical and pharmacokinetic study of rebeccamycin analogue NSC 655649 given daily for five consecutive days. J Clin Oncol 19: 2309-2318, 2001
15. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10: 1-10, 1989
16. National Cancer Institute: Common Toxicity Criteria, Version 2. Bethesda, MD, National Cancer Institute, 1999
17. Therase P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000
18. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004
19. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group Trial. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No. (14S) (July 15 Suppl.) p. 7022, 2004
20. Burstein HJ, Overmoyer B, Gelman R, et al.: Rebeccamycin analog for refractory breast cancer: A randomized phase II trial. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 22, No. (14S) (July 15 Suppl.), p. 547, 2004
21. Dowlati A, Posey J, Ramanathan RK, Rath, L, Sellers A, Schmotzer A, Ingalls S, Hoppel C, Ivy P, Remick SC: Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. Proc Am Soc Clin Oncol 22: abstract 1070, 2003
22. Lilenbaum R: Management of advanced non-small-cell lung cancer in elderly populations. Clin Lung Cancer 5: 169-173, 2003